Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Breast Cancer HR-positive HER2-negative Advanced breast cancer LEE011 ribociclib everolimus Afinitor exemestane Aromasin CDK CDK4 CDK6 CDK4/6 CDK4/6 inhibitor Phase III ER-positive PR-positive Postmenopausal Breast Neoplasms Sirolimus ribociclib + everolimus + exemestane
Lead Scientist at UCSF
- Hope Rugo
Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Novartis Pharmaceuticals
- Phase 1/2
- Study Type
- Last Updated